Table 2.
Geometric mean titres (GMTs) for competitive Luminex Immunoassay (cLIA) in milliMerck units per millilitre (mMu/mL) obtained at seven months (four weeks/one month after the third vaccine dose).
| Age range in years: | Number of patients: | HPV-6: | HPV-11: | HPV-16: | HPV-18: | |
|---|---|---|---|---|---|---|
| Seropositivity threshold values [31]: | 20 | 16 | 20 | 24 | ||
| Nelson et al. (17)a: | 11 – 15 | n = 8b | 154 | 222 | 409 | 61 |
| 16 – 21 | n = 13b | 52 | 72 | 137 | 36 | |
| Kumar et al. (16): | 18 – 35 | n = 32c | 14.7d | 32.6d | 36.4d | 11.3d |
| Gomez-Lobo et al. (15): | 12 – 18 | n = 7 (Kidney) | 1056 | 1303 | 6872 | 1619 |
| n = 1 (Liver) | 158 | 1882 | 824 | 1616 | ||
| Healthy population (26): | 9 – 15 | 929.2 (n = 917) | 1304.6 (n = 917) | 4918.5 (n = 915) | 1042.6 (n = 922) | |
| 16 – 26 | 545.0 (n = 3329) | 748.9 (n = 3353) | 2409.2 (n = 3249) | 475.2 (n = 3566) | ||
| 27 – 34 | 435.6 (n = 439) | 577.9 (n = 439) | 2348.5 (n = 435) | 385.8 (n = 501) |
a
Obtained 1–12 months after completion of the vaccination series.
b
Only 21/23 kidney transplant recipients with Luminex measures at seven months.
c
Only 32/46 transplant recipients with Luminex measures at seven months.
d
Kumar et al.(16) measured GMTs in milliMerck units per litre (mMu/L).